<DOC>
	<DOCNO>NCT00544687</DOCNO>
	<brief_summary>CRx-191 proprietary synergistic combination drug candidate evaluate CombinatoRx topical psoriasis therapy . CRx-191 identify via proprietary screen assay novel drug combination demonstrate enhanced inhibition tumor necrosis factor- alpha interferon-gamma release , cytokine implicate pathogenesis psoriasis .</brief_summary>
	<brief_title>Phase I Study Topical CRx-191 Normal Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Nortriptyline</mesh_term>
	<criteria>Subject must voluntarily give write informed consent Subject must least 18 year age Subject must healthy skin redden easily recognize area test field The physical examination must without disease finding unless investigator considers abnormality irrelevant outcome study Sexually active female childbearing potential either surgically sterile ( hysterectomy tubal ligation ) , use highly effective medically accept contraceptive regimen ; systemic contraceptive ( combined oral contraceptive , implant , injection ) , safe intrauterine device ( IUD ) Written informed consent obtain Acne , suntan , eczema , hyper hypopigmentation , tattoos test field Dark skin person whose skin color prevents ready assessment skin reaction Cardiac disease include recent myocardial infarction , degree heart block cardiac arrhythmia valvular heart disease Mania Narrow angle glaucoma Hyperthyroidism medical history , TSH &lt; LLN , receive thyroid medication Severe liver disease ( alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) laboratory value exceed 1.5x ULN ) Inflammatory dermatosis ( e.g . atopic dermatitis , psoriasis ) , bacterial , viral , fungal skin infection ; facial rosacea Active varicella , tuberculosis , syphilis postvaccine reaction Autoimmune disease ( e.g. , lupus erythematosis ) Known allergic reaction hypersensitivity component study preparation Allergy adhesives patch use occlusion study UV therapy four week study History malignancy ( except treat excised basal cell carcinoma ) Surgery within previous 3 month ( except minor cosmetic dental procedure ) History drug alcohol abuse ( define Investigator ) Symptoms clinically significant illness four week study may influence outcome study Positive human immunodeficiency virus ( HIV ) antibody Systemic treatment two week precede study may interact study drug , : Glucocorticoids ( po , im , iv ) , MAO inhibitor , Antidepressants , Antiseizure medication , Antipsychotics , Antihistamines Subjects require medication inhibit cytochrome P450 ( CYP450 ) 2D6 pathway : Quinidine , Cimetidine , Type 1 antiarrhythmic , Phenothiazines , Selective serotonin reuptake inhibitor fluoxetine , paroxetine , sertraline , reserpine , anticholinergic drug , sympathomimetic drug Participation another clinical trial and/or treatment receive investigational agent within one month initial dose study medication Female subject pregnant lactating Significant UV exposure four week study Unwilling unable comply requirement protocol , include presence condition ( physical , mental , social ) likely affect subject 's return followup visit schedule Other unspecified reason , opinion Investigator sponsor make subject unsuitable enrollment Subject institutionalized legal regulatory order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Skin</keyword>
	<keyword>Atrophy</keyword>
	<keyword>CRX-191</keyword>
	<keyword>mometasone furoate</keyword>
	<keyword>nortriptyline hydrochloride</keyword>
	<keyword>Skin Thickness Normal Healthy Volunteers</keyword>
</DOC>